Remdesivir for kidney transplant patients with mild COVID-19
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether giving remdesivir to kidney transplant patients who test positive for COVID-19 can prevent them from getting severely ill. It is for people who have already had at least three COVID-19 vaccine doses and are scheduled to receive a kidney transplant soon.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are on the kidney transplant waiting list and have a compatible organ offer, with the transplant happening within 1 to 5 days.
- You tested positive for COVID-19 (via a nasal swab) within the last 5 days.
- You have had at least three doses of a COVID-19 vaccine, and it has been at least 3 months since your last dose.
- You have no or only mild COVID-19 symptoms (like headache, sore throat, cough, or fatigue), but no fever above 38°C or shortness of breath in the last 48 hours.
- If you are a woman able to have children, you agree to avoid pregnancy during the study.
- You are not pregnant or breastfeeding.
- You do not need extra oxygen or have severe lung disease.
- You do not have a known allergy to remdesivir.
- You have not had an ABO-incompatible kidney transplant or certain other transplant treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what happens when people with kidney transplants get COVID-19. It may help improve how doctors monitor and manage COVID-19 in transplant recipients.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This trial studies a longer course of remdesivir combined with nirmatrelvir/ritonavir (Paxlovid) for immunocompromised patients who have persistent COVID-19. The goal is to see if this combination helps clear the virus better.
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
This trial tests a special machine that cleans a donated kidney before transplant to lower the chance of passing on a common virus (CMV). It may help people who are getting a kidney from a donor who had CMV.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.